Seasonal Affective Disorder Market Size & Share from 2022-2030

Due to various disorders and conditions such as seasonal affective disorder (SAD), blue light therapy has witnessed a significant demand globally. This has compelled various manufacturers to cater to such growing demands. The global light therapy market is expected to register at 4.8% over the forecast period, 2026.

Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114802/Light-Therapy-Market 

Market Dynamics: Attributed to various advantages such as increased blood circulation and cellular regeneration, acne treatment using LED light is gaining traction. Moreover, treatment through LED light treatment offers the benefits of red and blue light therapy over conventional light therapy. Such factors are driving growth of the light therapy market globally over the following decade.

Global Light Therapy Market to Grow at 4.8% CAGR throughout 2026

Segmentation Analysis: The light box segment among various among other products accounts for relatively high market share and will grow at 4.3% CAGR in the span of next ten years. Whereas, the homecare settings segment among various end users accounts for relatively high market share and will grow at a relatively high CAGR of 5.1% over the following decade. The white light among various types of light will witness a healthy growth in the span of next ten years.

Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114802/Light-Therapy-Market

Regional Analysis

Following Western Europe North America accounted for major market share of 42.5% in 2015 among various regions. Whereas, the APEJ market will expand at a relatively high CAGR of 6.5% over the following decade.

In 2014, the light therapy market in Latin America registered a 6.4% Y-o-Y growth rate. Whereas, the light therapy market in Eastern Europe will grow at 4.5% CAGR in the span of next ten years.

However, in 2014, the light therapy treatment market in Russia represented major market share in Eastern Europe. Russia will retain dominance in the region in the span of next ten years, growing at a 4.6% CAGR over the following decade.

Vendor Insights

Market players operating in the global light therapy market include Verilux, Inc., Koninklijke Philips N.V., Zepter International, Northern Light Technology, Beurer, Photomedex Inc, Lucimed SA, Nature Bright, Lumie, Chal-Tech-GmbH, Sphere Gadget Technologies and Aura Daylight.

Research Report Insights (RRI) is a leading market intelligence and consulting firm. We deliver a host of services including custom research reports, syndicated research reports, and consulting services which are personalised in nature. RRI delivers a complete packaged solution to clients; this combines current market intelligence, technology inputs, statistical anecdotes, valuable growth insights, 360-degree view of the competitive framework, and anticipated market trends.

Our research services cover global as well as regional emerging markets such as BRICS, GCC, and ASEAN. Our offerings cover a broad spectrum of verticals which include Oil and Gas, Chemicals, Materials, Energy, Technology, Automotive, and Retail. The operating model of RRI blends cross-disciplinary research experience to deploy insightful, in-depth, and actionable research.

Contact Us:

Research Report Insights

42 joseph street,

Portcarling P0B 1J0,

Muskoka, Ontario, Canada

T: +1-631-721-4201

Email: [email protected]

Web Site: http://www.researchreportinsights.com

Phone - (+91) 7875758555

Report Analysis@ https://www.researchreportinsights.com/report/rd/110114802/Light-Therapy-Market

This report studies the global market size of Pressure Infusion Cuffs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pressure Infusion Cuffs in these regions.

This report also studies the global Pressure Infusion Cuffs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Request a sample of this report@ https://www.orbisresearch.com/contacts/request-sample/2322852?utm_source=Mohit

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

AC Cossor & Son (Surgical)

Market size by End User

The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.

It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.

Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.

Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.

Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.

Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size  By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.

These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.

Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.

New York, NY 04 Mar 2021: The sleep disorder market size is anticipated to reach over USD 2.61 billion by 2026 according to a new research published by Polaris Market Research.

In 2017, the sleep apnea devices dominated the global market, in terms of revenue.

The treatment for include medication, better sleeping habits, and devices.

Medicines such as, Hetlioz (tasimelteon) by Vanda Pharmaceuticals, Intermezzo (zolpidem tartrate sublingual tablet) by Transcept Pharmaceuticals, and Silenor (doxepin) by Somaxon Pharma are some of the FDA approved drugs that are observed to be beneficial during the treatment of sleep disorders.

Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/sleep-disorder-market/request-for-sample The industry is segmented on the basis of disorder type, device, treatment, and geography.

Based on disorder type, the market is bifurcated into sleep apnea, sleep breathing disorders, insomnia, hypersomnia, circadian rhythm disorders, parasomnia, and sleep movement disorders.